Human fetal skin fibroblasts: Extremely potent and allogenic candidates for treatment of diabetic wounds

Larijani, Bagher; Ghahari, Aziz; Warnock, Garth L.; Aghayan, Hamid Reza; Goodarzi, Parisa; Falahzadeh, Khadijeh; Arjmand, Babak

doi:10.1016/j.mehy.2015.03.004

Cited by 24 publications

(16 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An additional interesting cell type, on this purpose, could be fetal fibroblasts. They were effectively applied to the treatment of diabetic wounds due to their immunoregulatory properties and cell matrix production [ 27 , 28 ]. We believe that the latter report further strengthens the principle of using hUCMS: in fact, they share with fetal fibroblasts some properties, such as immunomodulatory activity, fetal origin, and a myofibroblast identity.…”

Section: Discussionmentioning

confidence: 99%

Human Umbilical Cord Wharton Jelly-Derived Adult Mesenchymal Stem Cells, in Biohybrid Scaffolds, for Experimental Skin Regeneration

Montanucci

Pasquali

Ferri

et al. 2017

Stem Cells International

View full text Add to dashboard Cite

The ultimate goal for skin tissue engineering is to regenerate skin lesions to allow the full restoration of morphological and functional properties as what they were before injury. To this end, we have assembled a new prototype of a biomimetic human umbilical cord adult mesenchymal stem cell (hUCMS)/fibrin-based scaffold. We have fully characterized the proposed dermal equivalent (DE) in vitro, to assess morphological, functional, and biological properties of the encased cells. We transplanted DE subcutaneously into immunocompetent rodents, to verify its full biocompatibility. Finally, we studied DE graft effects on full-thickness wounds, in immunocompetent mice to demonstrate its capability to drive the healing process in the absence of significant scarring tissue. The excellent outcome of these in vivo studies fuels hope that this new approach, based on a biohybrid DE, may be applied to the operative treatment of skin lesions (i.e., diabetic foot ulcers and burns) in man.

show abstract

Section: Discussionmentioning

confidence: 99%

Human Umbilical Cord Wharton Jelly-Derived Adult Mesenchymal Stem Cells, in Biohybrid Scaffolds, for Experimental Skin Regeneration

Montanucci

Pasquali

Ferri

et al. 2017

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…Pragmatic optimization of cell source selection and processing is crucial within translational development and clinical implementation of cell therapies and related products. Iterative amelioration and successful application of standardized workflows have led to identify allogenic primary FPC sources as highly promising and efficient candidates for regenerative medicine (Hebda and Dohar, 1999;De Buys Roessingh et al, 2006;Mirmalek-Sani et al, 2006;Ferguson, 2007, 2008;Larijani et al, 2015;Grognuz et al, 2016b;Kim et al, 2018). Upon adequate isolation from fetal tissues (i.e., enzymatic or mechanical methods), culture-expansion and cryopreservation, progeny cells and derivatives present numerous advantages.…”

Section: Allogenic Fpc Technology For Translational Researchmentioning

confidence: 99%

Holistic Approach of Swiss Fetal Progenitor Cell Banking: Optimizing Safe and Sustainable Substrates for Regenerative Medicine and Biotechnology

Laurent

Hirt‐Burri

Scaletta

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Swiss Fetal Progenitor Cell Banking is proposed, achieving sustained standards and potential production of billions of affordable and efficient therapeutic doses. Thereby, the aim is to validate the core therapeutic value proposition, to increase awareness and use of standardized protocols for translational regenerative medicine, potentially impacting millions of patients suffering from cutaneous and musculoskeletal diseases. Alternative applications of FPC banking include biopharmaceutical therapeutic product manufacturing, thereby indirectly and synergistically enhancing the power of modern therapeutic armamentariums. It is hypothesized that a single qualifying fetal organ donation is sufficient to sustain decades of scientific, medical, and industrial developments, as technological optimization and standardization enable high efficiency.

show abstract

“…In fact, the fetus has a more efficient regeneration system to quickly restore tissue integrity and heal the wound in a scarless manner while adults' wounds are repaired with the formation of scar (28). Among different kinds of cells used for cell-based therapies for wound management of the skin, fetal cells present biological, technical, and therapeutic advantages over others, for instance they are differentiated cells with low immunogenic and high expansion and regeneration characteristics (29).…”

Section: Fetal Cell Therapy and Scarless Wound Healingmentioning

confidence: 99%

“…They can also proliferate and produce collagen at the same time, and stimulate extra cellular matrix replacement directly or indirectly in tissue repair process for migration to the wound area. Their capability to adapt to biomaterials and strong resistance to oxidative and physical stresses in wound environment, may lead to their durability in the wound milieu (29,33). Scarless wound healing in fetal skin at early gestation is a result of the unique cytokine or growth factor profile.…”

Section: Fetal Cell Therapy and Scarless Wound Healingmentioning

confidence: 99%

Scarless Wound Healing: Looking for a Single Remedy With Multiple Targets

et al. 2017

View full text Add to dashboard Cite

Context: Scars result from prolonged inflammatory phases and abnormal fibroproliferative responses in wounds. Regardless of beauty considerations that have profound psychological and social effects, scars can also have physical effects, such as growth constraints in children. Applying molecular and cellular mechanisms imitating the fetal scarless wound healing, brings about new and effective therapeutic strategies for alleviating scars. This review concentrated on innovative approaches, which simultaneously target multiple effective pathways in reducing scars. Evidence Acquisition: The most outstanding products for reducing scars, were TGF-β3 and IL-10, which failed in phase III clinical trial on their way to reach the market. In this review, multi-targeting remedies for reducing scars and their effective in vitro and in vivo mechanisms are discussed in details. There is also evidence in translation of these investigations to clinical trials. Results: MiRNAs are unique molecular components with pleiotropic actions, which target multiple signaling pathways in scars at the same time. Fetal cells, mesenchymal stem cells, and oral mucosal cells secrete a natural relevant concentration of growth factors and cytokines that are effective in scar reduction. Fat grafting is a promising treatment for scars, providing an appropriate extra cellular matrix with homing mesenchymal stem cells. Conclusions: Increasing the concentration of one growth factor or cytokine overexpressed in fetal scarless wound healing is not sufficient individually in scar reduction. Despite the profound effects of cells in scars, using biomimetic materials, which mimic the fetal cell microenviroment, should also be taken into account.

show abstract

Human fetal skin fibroblasts: Extremely potent and allogenic candidates for treatment of diabetic wounds

Cited by 24 publications

References 9 publications

Human Umbilical Cord Wharton Jelly-Derived Adult Mesenchymal Stem Cells, in Biohybrid Scaffolds, for Experimental Skin Regeneration

Human Umbilical Cord Wharton Jelly-Derived Adult Mesenchymal Stem Cells, in Biohybrid Scaffolds, for Experimental Skin Regeneration

Holistic Approach of Swiss Fetal Progenitor Cell Banking: Optimizing Safe and Sustainable Substrates for Regenerative Medicine and Biotechnology

Scarless Wound Healing: Looking for a Single Remedy With Multiple Targets

Contact Info

Product

Resources

About